Therapy related leukemias: Susceptibility, prevention and treatment

Leukemia and Lymphoma

Volumn 41, Issue 3-4, 2001, Pages 255-276

  Leone, G ^a   Voso, M T ^a   Sica, S ^a   Morosetti, R ^a   Pagano, L ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Acute leukemia; Secondary leukemia; Susceptibility; Therapy related leukemias; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ALKALOID; BLEOMYCIN; BUSULFAN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DNA; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; MELPHALAN; MYELOID LYMPHOID LEUKEMIA TRANSCRIPTION FACTOR; NITROSOUREA; PREDNISONE; PROCARBAZINE; RETINOID; SEMUSTINE; TENIPOSIDE; TOPOTECAN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE SULFATE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; ALLELE; ALLOGRAFT; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CARCINOGENIC ACTIVITY; CELL TRANSFORMATION; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME ABERRATION; CHROMOSOME BAND; CHROMOSOME DELETION 13; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 19; CHROMOSOME TRANSLOCATION 4; CHROMOSOME TRANSLOCATION 9; CLINICAL FEATURE; CYTOPENIA; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG MEGADOSE; FOLLOW UP; GENE MUTATION; GENETIC CODE; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; LATENT PERIOD; LYMPHOMA; MEDICAL ASSESSMENT; MONOCYTIC LEUKEMIA; MULTIPLE MYELOMA; MYELODYSPLASIA; NONHODGKIN LYMPHOMA; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TESTIS CANCER; TUMOR SUPPRESSOR GENE;

EID: 0034984527     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109057981     Document Type: Review

References (193)

1. Environment and Cancer: Who are susceptible?
2. Therapy related myelodysplastic syndromes
3. Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood
4. Cancer risk in first-degree relatives of children with malignant tumours (province of Trieste, Italy)
5. Increased risk of myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect
6. Prevalence of the inactivating 609C>T polymorphism in the NAD(P)H: Quinone oxidoreductase (NQO1) gene in patients with primary and therapy and therapy-related myeloid leukemia
7. Therapy related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohort of patients treated intensively for malignant diseases in the Copenhagen series
8. Sex differences in risk of second malignand tunours after Hodgkin's disease in childhood
9. Etoposide-related acute promyelocitic leukemia
10. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant diseases
11. Incidence, previous treatment and chromosome characteristics of secondary acute non-lymphocytic leukemia
12. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: Correlation between chromosomal abnormalities and prior therapy
13. Translocations, master genes, and differences between the origins of acute and chronic leukemias
14. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations
15. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation
16. Secondary leukemias induced by topoi-somerase-targeted drugs
17. Fluorescence in situ hybridization mapping of translocations and deletions involving the short arm of human chromosome 12 in malignant hematologic diseases
18. Acute nonlymphocytic leukemia. A delayed complication of Hodgkin's disease therapy: Analysis of 109 cases
19. Epipodophillotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer
20. The biology of alkylating-agent cellular injury
21. Second malignancies associated with chemotherapic agents
22. Acute leukaemia after busulphan
23. Melphalan may be more potent leukemogen than cyclophospamide
24. Therapy related leukemia and myelodisplastic syndrome: Clinical, cytogenetic, and prognostic features
25. Therapy related acute myeloid leukemia and myelodysplastic syndrome
26. Morphology and classification of the myelodysplastic syndromes and their pathologic variants
27. Secondary or therapy-related myelodysplasia and acute myeloid leukemia and their chromosome aberrations: Important to study but difficult to estabilishcausality
28. Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders
29. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia
30. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases
31. Chromosome pattern in juvenile chronic myelogenous leukemia, myelodysplastic syndrome, and acute leukemia associated with neurofibromatosis
32. Sequential development of Wilms tumor, T-cell acute lymphoblastic leukemia, medulloblastoma and myeloid leukemia in a child with type 1 neurofibromatosis: A clinical and cytogenetic case report
33. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1
34. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders
35. Myeloid malignancies induced by alkylating agents in Nf1 mice
36. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia
37. P53: Guardian of genome
38. The p53 gene in pediatric therapy-related leukemia and myelodysplasia
39. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma
40. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia
41. Binding of mismatched microsatellite DNA sequences by the human MSH2 protein
42. HMSH2 mutations in hereditary nonpolyposis corectal cancer childrens
43. Association of germ-line p53 mutation with MLL segmental jumping translocation in treatment-related leukemia
44. Frequent jumping translocations of chromosomal segments involving the ABL oncogene alone or in combination with CD3-MLL genes in secondary leukemias
45. Mechanism of action of teniposide (VM 26) and comparison with etoposide (VP16)
46. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation
47. Panhandle PCR strategy to amplify MLL genomic breakpoints in treatment-related leukemias
48. Therapy-related acute myeloid leukemia wit t(8,21), inv(16), and t(8,16): A report on 25 cases and review of the literature
49. Epipodophyllotoxins and secondary leukaemia
50. Chemotherapy-related - Late occurring - Philadelphia chromosome in AML, ALL and CML. Similar events related to treatment with DNA topoisomerase II inhibitors?
51. Epipophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer
52. Acute myeloid leukemia in children treated with epipodophillotoxins for acute lymphocytic leukemia
53. L-asparaginase may potentiate the leukemogenic effect of epipodophyllotoxins
54. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small cell carcinoma of the lung
55. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins
56. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia
57. Association of CYP3A4 genotype with treatment related leukemia
58. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements
59. Therapy-related acute promyelocytic leukemia with t(15,17) (q22,q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature
60. CBFA2 (AML1) translocations with novel partner chromosomes myeloid leukemias: Association with prior therapy
61. The partner gene of AML1 in t(16;21) myeloid malignancies in a novel member of the MTG8(ETO) family
62. An M11-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes
63. HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities
64. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: Correlation with scaffold attachment regions and topoisomerase binding sites
65. Common region of ALL-1 gene disrupted in epipodophyllotoxin-related secondary acute myeloid leukemia
66. Human trithorax gene rearrangements in therapy-related acute leukaemia after etoposide treatment
67. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children
68. An in vivo topoisomerase II cleavage site and DNase I Hypersensitive site clocalize near exon 9 in the MLL breakpoint cluster region
69. Topoisomerase II inhibitors induce DNA double strand breaks at a specific site within the AML1 locus
70. Clinical and cytogenetic correlation in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosomes no. 5 and 7
71. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14, patientsn from a single institution
72. GIMEMA Acute promyelocytic leukemia following previous malignancy. Report of 51 cases
73. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis
74. Acute promyelocytic leukemia with t(15-17) following inhibition of DNA topoisimerase II
75. Acute promyelocytic leukemia after treatment of malignant glioma in a patient with Von Recklinghausen's disease: Case report and revue of literature
76. Acute lymphoblastic leukaemia occurring as second malignancy; report of the GIMEMA Archive of Adult Acute Leukaemia
77. Acute leukaemia with t(4;11) in patients previously exposed to carcinogens
78. Distinct MLL gene rearrangements associated with successive acute monocytic and lymphoblastic leukemias in the same patient
79. Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities
80. Chronic myelocytic leukemia as a second neoplasia in the course of chronic myelogenous leukemia. Case report and revue of literature
81. Chronic myelogenous leukemia following radiotherapy and chemotherapy for non-Hodgkin lymphoma
82. Therapy related chronic myeloid leukemia: An epidemiological, clinical and pathogenetic appraisal
83. Therapy related myeloid leukemia
84. Hodgkin's disease and risk of acute leukemia in succesfully treated patients
85. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease
86. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: A population-based cohort study in the five nordic countries
87. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease
88. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease
89. Second cancer risk following Hodgkin's disease: A 20-year follow-up study
90. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease
91. Acute leukemia after the treatment of Hodgkin's disease
92. Primary cancer following Hodgkin's disease. Updated results of an Italian multicentric study
93. Leukemia complicating treatment for Hodgkin's disease. The experience of the British National Lymphoma Investigation
94. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher after combined modality programs than after chemotherapy alone and is correlated with the extend of radiotherapy and chemotherapy. A case control study
95. Risk of leukemia following treatment for non-Hodgkin's lymphoma
96. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas
97. Impact on second malignancy risk of combined use of radiation and chemotherapy for lymphoma
98. Secondary acute myeloid leukemia following treatment with VP 16-containing regimens for non-Hodgkin's lymphoma
99. The chemotherapy of plasma cell myeloma and the incidence of acute leukemia
100. A comparison of the incidence of the myelodisplasic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatement for myelomatosis
101. Preceding standard therapy is the likely cause of MDS after autotransplants for myeloma
102. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia
103. Second neoplasms after acute lymphoblastic leukemia in childhood
104. Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia
105. Outcome after cessation of therapy in childhood acute lymphoblastic leukaemia
106. Secondary haematological neoplasm after treatment of adult acute lymphoblastic leukaemia. Analysis of 1170 adult ALL patients enrolled in the GIMEMA trials
107. Treatment of polycythemia vera the use of hydroxyurea and piprobroman in 292 patients under the age of 65 years
108. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea. High proportion of cases with 17p deletion
109. Polycytemia vera treated with pipobroman as single agent low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-91)
110. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia
111. Therapy related leukemia and myelodysplastic syndrome in chronic lymphocyte leukemia
112. Increased incidence of second neoplasms in patients treated with interferon alfa for hairy cell leukemia. A clinicopathologic assessment
113. Second malignancies in patients with hairy cell leukemia in British Columbia. A 20 year expeience
114. Association of cancer of the breast and acute myelocytic leukemia
115. Leukemia in breast cancer patients following adjuvant chemotherapy or post-operative radiation the NSABP experience
116. Risk of leukemia after chemotherapy and radiation treatment for breast cancer
117. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer the eastern cooperative oncology group experience
118. Acute myeloid leukemia (AML) in NSABPT B25
119. Treatment related leuekmia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy. The University of Texas M.D. Anderson Cancer Center experience
120. High risk of therapy related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorouracile, mithoxantrone and tamoxifene for advanced cancer
121. Second primary malignancy after Hodgkin's disease, ovarian cancer and cancer of the testis a population-based cohort study
122. Acute non lymphocitic leukemia in patients with ovarian carcinoma following long term treatment with treosulfan (dihydroxybusulfan)
123. Risk of leukemia after platinum-based chemotherapy for ovarian cancer
124. Increased risk of myelodisplasia and leukemia after etoposide, cisplatin, and bleomycin for germ-cell tumours
125. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors
126. Risk of second neoplasms among long-term survivors of testicular cancer
127. Acute myelogenous leukemia after treatment for malignant germ cell tumors in children
128. Myelodisplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma
129. Myelodisplastic syndrome after autologous bone marrow transplantation. An additional late complication of curative cancer therapy
130. Acute myeloid leukemia and myelodisplasia following intensive chemotherapy for breast cancer
131. Secondary leukemia after autologous peripheral progenitor cell transplantation for breast cancer
132. Secondary leukaemia and myelodysplasia after autografting for lymphoma results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation
133. High risk of therapy related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphoma is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure
134. Treatment related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease
135. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant
136. Malignancies after hematopoietic stem cell transplantation. Many questions, some answers
137. Molecular genetic features of myelodysplastic syndromes (MDS)
138. Micro-satellite instability and p53 mutations in therapy related leukemia suggest mutator phenotype
139. Do mutations at the glycophorin locus in patients treated for childhood Hodgkin's disease predict secondary leukemia?
140. Predictive value of clonality assay in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant a single institution study
141. Non dysplastic myelodysplasia?
142. Modifying risks of secondary leukemias. Is drug scheduling important?
143. ATM mutations and phenotypes in ataxia-telengiectasia families in the British Isles. Expression of mutant ATM and the risk of leukemia, lymphoma and breast cancer
144. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome
145. Ataxia telangiectasia genes and predisposition to leukaemia, lymphoma and breast cancer
146. Bloom syndrome, a Mendellian prototype of somatic mutational disease
147. Hematologic abnormalities in Fanconi anemia an International Fanconi Anemia Registry Study
148. Neurofibromatosis and childhood leukaemia/lymphoma a population-based UKCCSG study
149. Relationship between cytotxicity and site specific DNA recombination after in vivo exposure of leukemia cells to etoposide
150. Prognosis and therapy of secondary myelodysplastic syndromes
151. Leukemia and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure
152. Treatment of myelodysplastic syndromes
153. Randomized study of 13-cis retinoic acid vs placebo in myelodysplastic disorders
154. Secondary leukemia responsive to retinoic acid with abnormal localization of RARα protein. A report of two cases
155. All-transretinoic acid tolerance and biological effects in myelodysplastic syndrome
156. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes
157. A patient-oriented approach to the treatment of myelodysplastic syndromes
158. A critical apparisal of low dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes
159. All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of "poor prognosis" acute myeloid leukemia
160. Effects of treatment with 5-Azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes
161. Amifostine suppresses apoptosis in myelodysplastic CD34+ cells and promotes progenitor growth via polyamine like effects
162. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome
163. Treatment of therapy related leukemia and myelodysplastic syndrome
164. Therapy related leukemia and myelodysplastic syndromes. Clinical, cytogenetic, and prognostic features
165. Intensive antileukemic treatement of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia
166. Intensive chemotherapy for poor prognosis myelodyplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the Research and Treatment in Cancer (EORTC-LCG)
167. Short remission durations in therapy related leukemia despite cytogenetic complete response to high high dose cytarabine
168. Therapy of secondary acute nonlymphocytic leukemia with cytarabine
169. Carboplatin plus cytarabine in the treatment of high-risk acute myeloblastic leukemia
170. Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy related acute myelogenous leukemia
171. Idarubicin, high dose Cytarabine and etoposide for remission induction in therapy related acute myeloid leukemia
172. FLAG (Fludarabin plus high dose cytarabin plus G-CSF)- an effective and tolerable protocol for the poor acute myeloid leukemia
173. Early allogeneic transplantation for refractory or relapsed leukaemia following remission induction with FLAG
174. Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia
175. The importance of diagnostic cytogenetics on outcome in AML analysis of 1612 patients enterd into MRC AML 10 trial
176. Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes
177. Outcome of secondary myeloid malignancy in Hodgkin's disease the BNLI experience
178. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS
179. Allogenic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome a survey by the Leukemia Working Party of the European Bone Marrow Transplantation Group (EBMTG)
180. Bone marrow transplantation for myelodysplasia and secondary acute non lymphoblastic leukemia
181. Allogenic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome
182. Busulfan based regimens and allogenic bone marrow transplantation in patients with myelodysplastic syndromes
183. Busulfan and cyclophosphamide as conditioning regimen for allogenic bone marrow tranplantation for myelodysplasia
184. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukemia
185. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia an EBMT survey
186. Bone Marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia
187. The Seattle experience with bone marrow transplantation (BMT) for myelodysplasia (MDS)
188. Allogenic bone marrow transplantation for myelodysplastic syndrome outcomes analysis according to IPSS score
189. Stem cell transplantation for secondary acute myeloid leukemia. Evaluation of transplantation as initial therapy or following induction chemotherapy
190. Allogenic bone marrow transplantation for secondary leukemia or myelodysplasia
191. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes early transplantation is associated with improved outcome
192. Bone marrow transplantation for therapy-related myelodysplasia comparison with primary myelodysplasia
193. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma